Nuage Therapeutics
We develop new selective and potent drugs for intrinsically disordered targets.
We develop new selective and potent drugs for intrinsically disordered targets.
Nuage Therapeutics is a biopharmaceutical startup based in Spain, founded in 2021. The company's mission revolves around developing new selective and potent drugs for intrinsically disordered targets. Leveraging biomolecular condensation and chemical biology, Nuage Therapeutics aims to create selective inhibitors of intrinsically disordered proteins involved in challenging indications that represent unmet medical needs. The most recent milestone for Nuage Therapeutics was its €12.00M Seed Round investment on 14 March 2023, with notable participation from Sofinnova Partners, Asabys Partners, CDTI, and BStartup. This investment signifies a vote of confidence from prominent investors in the potential of Nuage Therapeutics' innovative approach to drug development. Overall, Nuage Therapeutics holds promise as it operates in the biopharma, biotechnology, and pharmaceutical industries, addressing critical medical needs by targeting intrinsically disordered proteins. The recent significant investment further positions the company for continued growth and advancement in the development of novel therapeutics.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | €12.00M | 4 |
|
14 Mar 2023 |
No recent news or press coverage available for Nuage Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
